Nanosize delivery as an emerging platform for cancer therapy.
Li
Chun-Qi
CQ
Phylonix Pharmaceutical Company, Cambridge, Massachusetts, USA.
Zhang
Guang-Xian
GX
D016503:Drug Delivery Systems; D018014:Gene Transfer Techniques; D015316:Genetic Therapy / Q000379:methods; D006801:Humans; D007167:Immunotherapy / Q000379:methods; D053758:Nanoparticles / Q000737:chemistry; D036103:Nanotechnology / Q000379:methods*; D009369:Neoplasms / Q000235:genetics / Q000378:metabolism* / Q000628:therapy*; D009838:Oligodeoxyribonucleotides / Q000737:chemistry; D045663:Quantum Dots; D034741:RNA, Small Interfering / Q000378:metabolism; D019098:Telomerase / Q000235:genetics / Q000378:metabolism
D009838:Oligodeoxyribonucleotides; D034741:RNA, Small Interfering; D019098:Telomerase